BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pyrukynd (Mitapivat) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Pyrukynd (Mitapivat)\, from ClinicalTrial
 s.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04610866-10280@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20280228
DTEND;VALUE=DATE:20280229
SUMMARY:Pyrukynd (Mitapivat): Phase 1/2 readout est. (NCT04610866)
DESCRIPTION:Pyrukynd (Mitapivat)\, phase 1/2\, Sickle Cell Disease.\nStudy:
  Safety\, Tolerability\, Pharmacokinetics\, and Pharmacodynamics of Long-t
 erm Mitapivat Dosing in Subjects With Stable Sickle Cell Disease: An Exten
 sion of a Phase I Pilot Study of Mitapivat\nEstimated primary completion: 
 28 February 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/mit
 apivat#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT04610866
URL:https://assetmemo.bio/drug/mitapivat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05935202-10280@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Pyrukynd (Mitapivat): Phase 2 readout est. (NCT05935202)
DESCRIPTION:Pyrukynd (Mitapivat)\, phase 2.\nStudy: Safety and Efficacy of 
 Mitapivat Sulfate in Adult Patients With Erythrocyte Membranopathies\nEsti
 mated primary completion: 30 September 2028. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/mitapivat#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT05935202
URL:https://assetmemo.bio/drug/mitapivat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07517133-10280@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Pyrukynd (Mitapivat): Phase 3 readout est. (NCT07517133)
DESCRIPTION:Pyrukynd (Mitapivat)\, phase 3.\nStudy: A Study to Investigate 
 the Efficacy\, Pharmacokinetics\, and Safety of Mitapivat in Pediatric Par
 ticipants With α- or β-Non-Transfusion-Dependent Thalassemia\nEstimated 
 primary completion: March 2029. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/mitapivat#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07517133
URL:https://assetmemo.bio/drug/mitapivat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07506863-10280@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Pyrukynd (Mitapivat): Phase 3 readout est. (NCT07506863)
DESCRIPTION:Pyrukynd (Mitapivat)\, phase 3\, Transfusion-Dependent Beta Tha
 lassemia.\nStudy: A Study to Investigate the Efficacy\, Pharmacokinetics\,
  and Safety of Mitapivat in Pediatric Participants With Transfusion-Depend
 ent Alpha- or Beta-Thalassemia (α- or β-TDT)\nEstimated primary completi
 on: June 2029. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/mitapi
 vat#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07506863
URL:https://assetmemo.bio/drug/mitapivat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07656415-10280@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Pyrukynd (Mitapivat): Phase 3 readout est. (NCT07656415)
DESCRIPTION:Pyrukynd (Mitapivat)\, phase 3\, Sickle Cell Disease.\nStudy: A
  Study to Investigate the Effect of Mitapivat on Transfusion Burden in Sub
 jects With Sickle Cell Disease (SCD)\nEstimated primary completion: August
  2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/mitapivat#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07656415
URL:https://assetmemo.bio/drug/mitapivat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05777993-10280@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Pyrukynd (Mitapivat): Phase 4 readout est. (NCT05777993)
DESCRIPTION:Pyrukynd (Mitapivat)\, phase 4\, Sickle Cell Disease.\nStudy: A
  Study to Provide Access to Mitapivat for Participants Who Previously Part
 icipated in an Agios-Sponsored Mitapivat Study\nEstimated primary completi
 on: August 2029. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/mita
 pivat#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT05777993
URL:https://assetmemo.bio/drug/mitapivat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07055243-10280@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:Pyrukynd (Mitapivat): Phase 2 readout est. (NCT07055243)
DESCRIPTION:Pyrukynd (Mitapivat)\, phase 2.\nStudy: To Assess Safety of Mit
 apivat and Provide Proof of Concept of the Efficacy of the Drug in Patient
 s With RBC Membranopathies or CDAII.\nEstimated primary completion: Octobe
 r 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/mitapivat#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0705524
 3
URL:https://assetmemo.bio/drug/mitapivat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
